血管性血友病因子/凝血因子VIII在多发性骨髓瘤及其他血液系统恶性肿瘤中血栓形成与癌症进展中的作用
综述探讨多发性骨髓瘤(MM)及其他血液系统恶性肿瘤中癌症相关血栓形成(CAT)的病理生理机制,重点总结血管性血友病因子(VWF)/凝血因子VIII(FVIII)在血栓风险中的作用及参与疾病进展的新证据。
要点
- MM患者血栓发生率极高,尽管广泛使用血栓预防药物仍存在未满足的临床需求。
- MM血栓形成机制多因素,包括VWF水平升高、活化蛋白C抵抗、纤溶受损及凝血酶生成异常。
- 特定研究中高血浆VWF水平与静脉血栓栓塞风险及总生存期降低相关。
核心结论
- 综述总结当前证据,阐述MM中血栓形成的病理生理机制,并聚焦VWF/FVIII在血液系统恶性肿瘤中的血栓风险作用及参与疾病进展的新证据。
研究设计与样本
- 综述,检索范围未在摘要中报告。
主要发现
- MM患者呈现高凝表型,潜在 contributory 因素包括VWF水平升高、活化蛋白C抵抗、纤溶受损和凝血酶生成异常。
- 抗骨髓瘤治疗对内皮的毒性作用及对血栓的贡献已被广泛描述。
- 在异质性MM及其他血液系统恶性肿瘤患者队列中报告了血浆VWF/FVIII水平升高。
- 特定研究中,高血浆VWF水平与VTE风险及总生存期降低相关。
- 某些实体器官恶性肿瘤中VWF与ADAMTS-13轴失调明显,并与晚期疾病和血栓形成相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cancer associated thrombosis (CAT) is associated with significant morbidity and mortality, highlighting an unmet clinical need to improve understanding of the pathophysiology of CAT. Multiple myeloma (MM) is associated with one of the highest rates of thrombosis despite widespread use of thromboprophylactic agents. The pathophysiology of thrombosis in MM is multifactorial and patients with MM appear to display a hypercoagulable phenotype with potential contributory factors including raised von Willebrand factor (VWF) levels, activated protein C resistance, impaired fibrinolysis, and abnormal thrombin generation. In addition, the toxic effect of anti-myeloma therapies on the endothelium and contribution to thrombosis has been widely described. Elevated VWF/factor VIII (FVIII) plasma levels have been reported in heterogeneous cohorts of patients with MM and other hematological malignancies. In specific studies, high plasma VWF levels have been shown to associate with VTE risk and reduced overall survival. While the mechanisms underpinning this remain unclear, dysregulation of the VWF and A Disintegrin And Metalloprotease Thrombospondin type 1, motif 13 (ADAMTS-13) axis is evident in certain solid organ malignancies and correlates with advanced disease and thrombosis. Furthermore, thrombotic microangiopathic conditions arising from deficiencies in ADAMTS-13 and thus an accumulation of prothrombotic VWF multimers have been reported in patients with MM, particularly in association with specific myeloma therapies. This review will discuss current evidence on the pathophysiological mechanisms underpinning thrombosis in MM and in particular summarize the role of VWF/FVIII in hematological malignancies with a focus on thrombotic risk and emerging evidence for contribution to disease progression.
引用
- Comerford C, Glavey S, Quinn J, et al. The role of VWF/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies. J Thromb Haemost. 2022. PMID: 35644028. doi:10.1111/jth.15773
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。